ACTG A5178: LONG-TERM ANTIVIRAL MANAGEMENT OF HCV AND HIV-1 COINFECTED SUBJECTS

ACTG A5178：HCV 和 HIV-1 合并感染受试者的长期抗病毒治疗

• 批准号: 7605734
• 负责人: JUDITH Ann ABERG
• 金额: $ 0.22万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605734
• 关键词: AIDS clinical trial group; Antiviral Agents; Cirrhosis; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; HIV; HIV-1; Hepatitis C; Hepatitis C virus; Infection; Institution; Interferon-alpha; Label; Liver Fibrosis; Morbidity - disease rate; Patients; Pharmaceutical Preparations; Phase; Rate; Research; Research Personnel; Resources; Ribavirin; Source; Standards of Weights and Measures; United States National Institutes of Health; Upper arm; Venipunctures; Work; liver biopsy; mortality; outcome forecast

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Patients with HIV are often co-infected with Hepatitis C virus (HCV), and the combination of these two infections leads to a worse prognosis for the HCV infection with respect to progression to cirrhosis. This is a multicenter, phase II, open-label, 2-arm, long-term (90 wk) trial of PEG-IFN (SQ qw)/ribavirin (po qd) in patients who are HCV-therapy na¿ve or who have failed to clear HCV with standard IFNa to determine whether it slows the rate of progression of hepatic fibrosis. While taking the drugs patients will undergo venipunctures and liver biopsies. Worldwide this is a significant problem leading to a great deal of morbidity and mortality. This will seek to determine whether this form of therapy works in a preliminary fashion.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以出现在其他 CRISP 条目中 列出的机构是。 对于中心来说，它不一定是研究者的机构。 HIV 患者通常同时感染丙型肝炎病毒 (HCV)，这两种感染的结合会导致 HCV 感染进展为肝硬化的预后较差。这是一项多中心、II 期、开放标签的研究。 ，在未接受 HCV 治疗的患者中进行 PEG-IFN (SQ qw)/利巴韦林 (po qd) 的 2 组长期（90 周）试验或未能用标准 IFNa 清除 HCV 以确定其是否能减缓肝纤维化进展速度的患者，在全世界范围内，这是一个导致大量发病率和肝纤维化的重大问题。这将试图初步确定这种治疗形式是否有效。